Dr. Arvin Yang is the Early Asset Development Lead for Oncology at Bristol-Myers Squibb (BMS). Previously, as the group director and medical lead for Global Clinical Research at BMS, he oversaw the development of the checkpoint inhibitor immunotherapies nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4). His current work involves developing other promising immunotherapies in order to get them into the clinic where they can benefit more patients. Dr. Yang is a member of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.
Let's spread the word about Immunotherapy! Click to share this page with your community.